Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Snags Life Technologies as Latest Co-Marketing Partner for SureSelect Target-Enrichment System

Premium

Agilent Technologies and the Applied Biosystems segment of Life Technologies said this week that they have signed a co-marketing agreement related to targeted resequencing.

Under the terms of the agreement, Agilent's SureSelect Target Enrichment System has been optimized for the ABI SOLiD sequencing platform and the firms have agreed to co-market the combined solution.

The agreement follows a similar pact that Agilent signed with Illumina in April. Under the terms of that deal, the companies agreed to co-market the SureSelect system with Illumina's Genome Analyzer II sequencer.

Agilent said in a statement that it made the SureSelect system available to some researchers using the SOLiD system on an early-access basis, including John McPherson, director of cancer genomics at the Ontario Institute for Cancer Research, which currently has seven SOLiD systems installed.

McPherson said in a statement that OICR will "target several genomic regions with the SureSelect solution for sequencing on the SOLiD platform."

He added that the "combination of the SureSelect enrichment and the accuracy of the SOLiD System will enable us to cost-effectively assess genetic variation across multiple tumor samples."

Agilent launched the SureSelect system in February (see BAN 2/10/2009). It includes customer-specified mixtures of up to 55,000 biotinylated RNA probes, delivered in single tubes. The capture probes are 120 base pairs long, which the company said is "the longest currently on the market for this application."

The company released an on-array version of the SureSelect system in July (see BAN 7/14/2009).

Users can design custom SureSelect mixtures using the Agilent eArray online design tool, which contains "many key genomes" and also lets users upload their own sequences, the company said.

The target-enrichment market, while relatively new, is increasingly competitive. Agilent's SureSelect is up against Roche NimbleGen's array-based sequence capture service; an in-solution product from RainDance Technologies called RainStorm; Febit, which provides a service called HybSelect; and Olink Genomics, which just recently launched its own sequence-capture service (see BAN 9/15/2009). Other players in the market include Fluidigm and LC Sciences.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.